Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Golden Bifid
- Development stage
- Phase 3
- Lead developer
- Shuangqi Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Golden Bifid is a triple-viable probiotic pharmaceutical preparation containing *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*. It is primarily indicated for the treatment of intestinal flora imbalance and associated gastrointestinal conditions such as diarrhea, constipation, and abdominal distension. In clinical research, particularly in China, it is evaluated for its ability to modulate the immune response and maintain intestinal barrier integrity in critically ill patients, including those with severe trauma or sepsis. By replenishing beneficial bacteria, it helps inhibit the growth of pathogenic microorganisms and reduces the translocation of endotoxins. It is manufactured by Inner Mongolia Shuangqi Pharmaceutical and is regulated as a drug in China.
- Brand names
- Golden BifidJin Shuang Qi
- Other names
- Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis triple viable preparationBifidobacterium Triple Viable CapsulesBifidobacterium Triple Viable Tablets
Beyond the preview
Go deeper on Golden Bifid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Golden Bifid.